{"commentary":{"count":18,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":13,"youtube":3,"podcast":2},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03775265\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT03775265","nct_id":"NCT03775265","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct03775265. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Patients undergo RT (3DCRT or IMRT) daily Monday-Friday for up to 7-8 weeks. Patients also receive chemotherapy based on physician's choice of gemcitabine IV twice weekly for 6 weeks concurrent with RT, or cisplatin IV weekly for 6 weeks concurrent with RT, or fluorouracil IV on same days as doses 1-5 and 16-20 of radiation therapy and mitomycin IV on day 1 of radiation therapy in the absence of disease progression or unacceptable toxicity. Patients also undergo a TURBT with bladder biopsy at randomization and week 18 as well as cystoscopy at randomization, at weeks 18, 30, 42, 54, then every 3 months through year 2, followed by every 6months through year 5 and CT or MRI at randomization, at weeks 18, 30, 42, 54, then every 6 months through year 2, followed by every 12 months through year 5.","label":"Arm I (RT, chemotherapy)","type":"ACTIVE_COMPARATOR"},{"description":"Patients undergo RT (3DCRT or IMRT) daily Monday-Friday for up to 7-8 weeks and receive chemotherapy based on physician's choice as in Arm I. Patients also receive atezolizumab IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 9 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo a TURBT with bladder biopsy at randomization and week 18 as well as cystoscopy at randomization, at weeks 18, 30, 42, 54, then every 3 months through year 2, followed by every 6months through year 5 and CT or MRI at randomization, at weeks 18, 30, 42, 54, then every 6 months through year 2, followed by every 12 months through year 5.","label":"Arm II (RT, chemotherapy, atezolizumab)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-06-01","type":"ESTIMATED"},"conditions":["Bladder Urothelial Carcinoma","Muscle Invasive Bladder Carcinoma","Stage II Bladder Cancer AJCC v8","Stage IIIA Bladder Cancer AJCC v8"],"enrollment":{"count":475,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Atezolizumab","type":"DRUG"},{"name":"Biopsy of Bladder","type":"PROCEDURE"},{"name":"Cisplatin","type":"DRUG"},{"name":"Computed Tomography","type":"PROCEDURE"},{"name":"Cystoscopy","type":"PROCEDURE"},{"name":"Fluorouracil","type":"DRUG"},{"name":"Gemcitabine","type":"DRUG"},{"name":"Magnetic Resonance Imaging","type":"PROCEDURE"},{"name":"Mitomycin","type":"DRUG"},{"name":"Quality-of-Life Assessment","type":"OTHER"},{"name":"Radiation Therapy","type":"RADIATION"},{"name":"Survey Administration","type":"OTHER"},{"name":"Transurethral Resection of Bladder Tumor","type":"PROCEDURE"}],"last_update":"2026-08-28","lead_sponsor":"National Cancer Institute (NCI)","official_title":"Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2027-06-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Bladder intact event-free survival (BI-EFS)","timeFrame":"From the date of randomization to the first documentation of a BI-EFS event, assessed up to 5 years"}],"references":[],"start_date":{"date":"2019-06-03","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer","url":"https://clinicaltrials.gov/study/NCT03775265"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct03775265"}